CMSFinal Rule

Medicare Program: End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals with Acute Kidney Injury, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model

HealthcareFinance & Banking

Summary

This regulation updates how Medicare pays for kidney dialysis services and quality care for patients with kidney failure. It aims to improve the quality of dialysis treatment and gives patients more choices in how they receive care while adjusting payment rates that hospitals and dialysis centers receive.

Key Points

  • 1Medicare is changing how much it pays dialysis centers and hospitals for treating patients with end-stage renal disease (permanent kidney failure requiring ongoing dialysis)
  • 2The rule establishes a new quality incentive program that rewards dialysis providers for meeting better health outcome standards
  • 3It creates a new payment model allowing patients with acute kidney injury to receive dialysis services while maintaining coverage
  • 4Dialysis centers will be evaluated on patient health metrics and quality measures, with payments adjusted based on performance
  • 5The changes affect millions of Medicare patients with kidney disease and the hospitals, dialysis clinics, and medical providers that treat them

Impact Assessment

If you are a dialysis center or hospital, this means you will receive adjusted Medicare payment rates and must implement quality reporting requirements; if you are a patient with kidney failure, this means you may have expanded treatment options and your care quality will be monitored under new incentive programs.

Impact Level
Significant
Geographic Scope

National

Compliance Cost

Significant

Who is Affected
Healthcare ProvidersConsumers

Key Dates

Published

November 24, 2025

Regulatory Connections

Amends CFR Sections
42 CFR Part 41342 CFR Part 488
Other Documents in This Rulemaking (CMS-2025-0240)

This summary is for informational purposes only. It may not capture all nuances of the regulation. Always refer to the official text for authoritative information.